As previously mentioned, a few studies determined Romo1 to be a potential prognostic biomarker in patients with HCC and NSCLC[14, 16, 17], and multiple in vitro studies demonstrated Romo1’s role in cancer biology; therefore, we could hypothesize that Romo1 might have clinical significance in CRC. The gene discussed is ROMO1; the disease is cancer.